Working… Menu

Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03034707
Recruitment Status : Completed
First Posted : January 27, 2017
Last Update Posted : April 19, 2019
Johns Hopkins University
Boston Medical Center
Children's Mercy Hospital Kansas City
Information provided by (Responsible Party):
University of Minnesota

Brief Summary:
The B vitamin biotin is widely available as an over the counter supplement, often advertised and used to promote health of hair, skin and nails. Commercially available over the counter biotin supplements contain dose ranges up to 10 mg/day (ie 333 times higher than the recommended dietary allowance). The biotin molecule is also sometimes used as part of the lab technology to measure hormone and protein levels in the blood. It is possible that high doses of ingested biotin may interfere with accurate hormone or protein measurement using biotin related in vitro measurement systems. Such interference, if present, could lead to misdiagnosis. The study will analyze laboratory levels obtained with streptavidin-biotin assay systems while ingesting biotin in currently available high dose supplements. The data will be compared to measurements obtained prior to and one week after stopping the biotin supplement.

Condition or disease Intervention/treatment Phase
Thoracic Diseases Parathyroid Diseases Dietary Supplement: biotin Not Applicable

Detailed Description:

Specimens will be collected by venipuncture at 3 time points, including baseline (time 0), after one week of biotin supplementation (time 1, day 7), and then one week later (time 2, day 14). The time 1 specimen will be drawn approximately 2 hours after the last ingested dose of biotin on day 7. Specimen collection will include three 10 ml red top (no gel) tubes at each timepoint.

Specimens will be separated for isolation of serum using routine methods of the clinical chemistry laboratory. Serum will be stored at -80 degrees C until batch measurements as described Measurements Biotin levels will be measured on each sample. Hormone measurements will be performed using specific commercially available streptavidin-biotin assays and using different analyzers as indicated below. Immunoassay methods, not employing biotin-streptavidin methodology, will be used for negative assay controls.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing
Study Start Date : April 2016
Actual Primary Completion Date : October 2016
Actual Study Completion Date : December 31, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hormones
Drug Information available for: Biotin

Arm Intervention/treatment
Experimental: Biotin arm
biotin 10 mg/day for 7 days
Dietary Supplement: biotin

Primary Outcome Measures :
  1. Hormone measurements TSH, PTH, Total T4, free T4, total T3, free T3, prolactin [ Time Frame: Change from baseline, at 7 days, at 14 days ]
    Hormone measurements using biotinylated assay conducted in certified labratory using the standard lab ranges for each test.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Healthy adults

Exclusion Criteria:

  1. Pregnancy or lactation
  2. Known thyroid disease (goiter, abnormal thyroid state),
  3. Thyroid hormone treatment,
  4. Over the counter dietary/ nutritional supplement use currently or within the last 2 weeks (excluding standard multivitamin preparations containing no more than 100% of the daily value for biotin and calcium),
  5. Anticonvulsants,
  6. Night shift work, smokers, adults lacking capacity to consent for themselves

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03034707

Sponsors and Collaborators
University of Minnesota
Johns Hopkins University
Boston Medical Center
Children's Mercy Hospital Kansas City
Layout table for investigator information
Principal Investigator: Lynn A Burmeister, MD Univ of Minnesota
Study Director: Angela Radulescu, MD Univ of Minnesota
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Minnesota Identifier: NCT03034707    
Other Study ID Numbers: 1602M84022
First Posted: January 27, 2017    Key Record Dates
Last Update Posted: April 19, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by University of Minnesota:
biotin pharmacokinetic
biotinylated assay
hormone measurement
Additional relevant MeSH terms:
Layout table for MeSH terms
Thoracic Diseases
Parathyroid Diseases
Respiratory Tract Diseases
Endocrine System Diseases
Vitamin B Complex
Physiological Effects of Drugs